Related Experiment Video
Updated: Oct 14, 2025

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
Published on: January 28, 2020
Circulating SERPINA3 improves prognostic stratification in patients with a de novo or worsened heart failure
Leen Delrue1, Marc Vanderheyden1, Monika Beles1
1Cardiovascular Center, OLV Hospital, Moorselbaan 164, Aalst, 9300, Belgium.
Insights
Elevated serpin peptidase inhibitor, clade A member 3 (SERPINA3) levels in heart failure (HF) patients predict increased mortality and hospital readmissions. This biomarker aids in identifying high-risk HF patients for better prognostic stratification.
Area of Science:
- Cardiology
- Biomarker Discovery
- Heart Failure Research
Background:
- Heart failure (HF) poses a significant clinical challenge with a need for improved prognostic markers.
- Existing risk stratification models for HF can be enhanced with novel biomarkers.
Purpose of the Study:
- To investigate the prognostic relevance of serpin peptidase inhibitor, clade A member 3 (SERPINA3) in patients with de novo or worsened heart failure.
- To determine if SERPINA3 levels can predict mortality and cardiovascular readmissions in HF patients.
Main Methods:
- Analysis of myocardial gene and circulating SERPINA3 levels in heart failure patients (survivors vs. non-survivors) and controls.
- Validation in an independent cohort of 387 patients with de novo or worsened HF, assessing SERPINA3 levels against mortality and readmission endpoints.
- Multivariate analysis incorporating established clinical risk factors.
Main Results:
- Myocardial and circulating SERPINA3 levels were significantly up-regulated in non-survivors compared to survivors.
- Elevated SERPINA3 levels (>316 μg/mL) in the validation cohort were associated with increased all-cause mortality (HR: 2.4) and composite of mortality/unplanned cardiovascular readmission (HR: 2.0).
- SERPINA3 remained an independent predictor of mortality in multivariate analysis, alongside age, gender, ST2, glomerular filtration, and pulmonary capillary wedge pressure.
Conclusions:
- Increased SERPINA3 levels (>316 μg/mL) are associated with higher mortality and unplanned cardiac readmission in patients with de novo or worsened HF.
- Elevated SERPINA3 identifies a subgroup of HF patients at higher mortality risk, complementing existing clinical predictors.
- Further prospective studies are warranted to validate SERPINA3's role in HF prognostic stratification.
Aims:
We investigated the prognostic relevance of serpin peptidase inhibitor, clade A member 3 (SERPINA3) in patients admitted with a de novo or worsened heart failure (HF).
Methods And Results:
In the first stage, 83 HF-related left ventricular (LV) transcripts were examined in patients with congestive cardiomyopathy (CCMP, n = 44) who died within 5 years and compared with age-matched and haemodynamically matched CCMP survivors (n = 39) and controls with normal LV function (n = 17). Among 14 differentially expressed transcripts, myocardial gene and circulating SERPINA3 levels were up-regulated in non-survivors vs. survivors (2.40 ± 3.66 vs. 0.36 ± 0.22 units, P < 0.01 and 334.7 ± 138.7 vs. 228.2 ± 83.1 μg/mL, P < 0.01, respectively). While no significant transmyocardial gradient was detected, cytokine stimulation of human endothelial cells induced SERPINA3 secretion. In an independent validation cohort with a de novo or worsened HF (n = 387), circulating SERPINA3 levels > 316 μg/mL were associated with increased all-cause mortality {hazard ratio [HR] [95% confidence interval (CI)]: 2.4 [1.5-3.9], P = 0.0002} and its composite with unplanned cardiovascular readmission [HR (95% CI): 2.0 (1.2-3.3), P = 0.004]. Patients with elevated SERPINA3 levels and elevated either N-terminal pro brain natriuretic peptide or ST2 showed worse freedom from both endpoints. In a multivariate analysis, including established clinical risk factors, SERPINA3 remained independent predictor of all-cause mortality together with age, gender, ST2, glomerular filtration, and pulmonary capillary wedge pressure.
Conclusion:
In patients with a de novo or worsened HF, increased SERPINA3 levels > 316 μg/mL are associated with increased mortality or unplanned cardiac readmission. Elevated SERPINA3 levels on top of established clinical predictors appear to identify a subgroup of HF patients at higher mortality risk. Prospective studies should further validate its value in prognostic stratification of HF.
More Related Videos
12:45Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
Published on: December 11, 2017
14:35Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
Published on: April 17, 2021
Related Concept Videos
Heart Failure IV: Classification and Diagnostic Evaluation
Heart Failure V: Medical Management
Heart Failure III: Clinical Manifestations
Heart Failure II: Pathophysiology
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System